| 1001_Durham |
2016 VAM: 1001 – Allergen Immunotherapy, Today and Tomorrow: Session I. Inhalant Allergens for Allergic Rhinitis and Asthma |
CME |
| 1001_Epstein |
2016 VAM: 1001 – Allergen Immunotherapy, Today and Tomorrow: Session I. Inhalant Allergens for Allergic Rhinitis and Asthma |
CME |
| 1001_Larche |
2016 VAM: 1001 – Allergen Immunotherapy, Today and Tomorrow: Session I. Inhalant Allergens for Allergic Rhinitis and Asthma |
CME |
| 1001_Sette |
2016 VAM: 1001 – Allergen Immunotherapy, Today and Tomorrow: Session I. Inhalant Allergens for Allergic Rhinitis and Asthma |
CME |
| 1001_Wambre |
2016 VAM: 1001 – Allergen Immunotherapy, Today and Tomorrow: Session I. Inhalant Allergens for Allergic Rhinitis and Asthma |
CME |
| 1003_Bacchetta |
2016 VAM: 1003 – How Translational Research is Shifting the Treatment Paradigm from Symptom Management to Cure |
CME |
| 1003_Lukacs |
2016 VAM: 1003 – How Translational Research is Shifting the Treatment Paradigm from Symptom Management to Cure |
CME |
| 1003_Novak |
2016 VAM: 1003 – How Translational Research is Shifting the Treatment Paradigm from Symptom Management to Cure |
CME |
| 1003_Puck |
2016 VAM: 1003 – How Translational Research is Shifting the Treatment Paradigm from Symptom Management to Cure |
CME |
| 1003_Valenta |
2016 VAM: 1003 – How Translational Research is Shifting the Treatment Paradigm from Symptom Management to Cure |
CME |
| 1006_Butterfield |
2016 VAM: 1006 – Masqueraders of Anaphylaxis/Angioedema |
CME |
| 1006_Carter |
2016 VAM: 1006 – Masqueraders of Anaphylaxis/Angioedema |
CME |
| 1006_Cicardi |
2016 VAM: 1006 – Masqueraders of Anaphylaxis/Angioedema |
CME |
| 1006_Druey |
2016 VAM: 1006 – Masqueraders of Anaphylaxis/Angioedema |
CME |
| 1006_Khoury |
2016 VAM: 1006 – Masqueraders of Anaphylaxis/Angioedema |
CME |
| 1006_Zuraw |
2016 VAM: 1006 – Masqueraders of Anaphylaxis/Angioedema |
CME |
| 1008_Bachert |
2016 VAM: 1008 – Pathogenesis of Chronic Rhinosinusitis |
CME |
| 1008_Boyce |
2016 VAM: 1008 – Pathogenesis of Chronic Rhinosinusitis |
CME |
| 1008_Cahill |
2016 VAM: 1008 – Pathogenesis of Chronic Rhinosinusitis |
CME |
| 1008_Kato |
2016 VAM: 1008 – Pathogenesis of Chronic Rhinosinusitis |
CME |
| 1008_Kowalski |
2016 VAM: 1008 – Pathogenesis of Chronic Rhinosinusitis |
CME |
| 1202_Bonadonna |
2016 VAM: 1202 – Diagnostic Challenges in Mastocytosis: Serum Tryptase, Allele-Specific PCR and GI Pathology |
CME |
| 1202_Butterfield |
2016 VAM: 1202 – Diagnostic Challenges in Mastocytosis: Serum Tryptase, Allele-Specific PCR and GI Pathology |
CME |
| 1202_Metcalfe |
2016 VAM: 1202 – Diagnostic Challenges in Mastocytosis: Serum Tryptase, Allele-Specific PCR and GI Pathology |
CME |
| 1202_Orfao |
2016 VAM: 1202 – Diagnostic Challenges in Mastocytosis: Serum Tryptase, Allele-Specific PCR and GI Pathology |
CME |
| 1205 Hershey |
2016 VAM: 1205 – Lessons from Functional Genomics: New Data from the AADCRC |
CME |
| 1205_Raby |
2016 VAM: 1205 – Lessons from Functional Genomics: New Data from the AADCRC |
CME |
| 1205_Rothenberg |
2016 VAM: 1205 – Lessons from Functional Genomics: New Data from the AADCRC |
CME |
| 1206 Bachert |
2016 VAM: 1206 – Inflammatory Origins of CRS: Uncovering Opportunities for Disease Prevention and Modification |
CME |
| 1206 Wagenmann |
2016 VAM: 1206 – Inflammatory Origins of CRS: Uncovering Opportunities for Disease Prevention and Modification |
CME |
| 1206_Kern |
2016 VAM: 1206 – Inflammatory Origins of CRS: Uncovering Opportunities for Disease Prevention and Modification |
CME |
| 1206_Peters |
2016 VAM: 1206 – Inflammatory Origins of CRS: Uncovering Opportunities for Disease Prevention and Modification |
CME |
| 1505_Caubet |
2016 VAM: 1505 – FPIES: What We Know, What We Don’t Know and What We Still Need to Know |
CME |
| 1505_Groetch |
2016 VAM: 1505 – FPIES: What We Know, What We Don’t Know and What We Still Need to Know |
CME |
| 1505_Nowak-Wegrzyn |
2016 VAM: 1505 – FPIES: What We Know, What We Don’t Know and What We Still Need to Know |
CME |
| 1505_Q&A |
2016 VAM: 1505 – FPIES: What We Know, What We Don’t Know and What We Still Need to Know |
CME |
| 1506_Chambers |
2016 VAM: 1506 – The Safety of Asthma and Allergy Medications During Pregnancy: New Horizons |
CME |
| 1506_Johnson |
2016 VAM: 1506 – The Safety of Asthma and Allergy Medications During Pregnancy: New Horizons |
CME |
| 1506_Namazy |
2016 VAM: 1506 – The Safety of Asthma and Allergy Medications During Pregnancy: New Horizons |
CME |
| 1506_Q&A |
2016 VAM: 1506 – The Safety of Asthma and Allergy Medications During Pregnancy: New Horizons |
CME |
| 1801 Cloutier |
2016 VAM: 1801 – What Can Implementation Research Teach Us About the Management of Asthma? |
CME |
| 1801_Apter |
2016 VAM: 1801 – What Can Implementation Research Teach Us About the Management of Asthma? |
CME |
| 1802 Simon |
2016 VAM: 1802 – Management of Atopic Dermatitis: What’s New? |
CME |
| 1802_Beck |
2016 VAM: 1802 – Management of Atopic Dermatitis: What’s New? |
CME |
| 1802_Leung |
2016 VAM: 1802 – Management of Atopic Dermatitis: What’s New? |
CME |
| 1802_Q&A |
2016 VAM: 1802 – Management of Atopic Dermatitis: What’s New? |
CME |
| 1803 Teng |
2016 VAM: 1803 – Automating Pollen Identification/NAB |
CME |
| 1803_Chapman |
2016 VAM: 1803 – Automating Pollen Identification/NAB |
CME |
| 1803_Glaum |
2016 VAM: 1803 – Automating Pollen Identification/NAB |
CME |
| 1805 Bonilla |
2016 VAM: 1805 – Secondary Immune Deficiencies (Non-HIV) |
CME |
| 1805_Ballow |
2016 VAM: 1805 – Secondary Immune Deficiencies (Non-HIV) |
CME |
| 1805_Nicholas |
2016 VAM: 1805 – Secondary Immune Deficiencies (Non-HIV) |
CME |
| 1806 Hogan |
2016 VAM: 1806 – Non-IgE-Mediated Gastrointestinal Food Allergies in Children and Adults |
CME |
| 1806 Nowak-Wegrzyn |
2016 VAM: 1806 – Non-IgE-Mediated Gastrointestinal Food Allergies in Children and Adults |
CME |
| 1806_Green |
2016 VAM: 1806 – Non-IgE-Mediated Gastrointestinal Food Allergies in Children and Adults |
CME |
| 1808 Gern |
2016 VAM: 1808 – Microbial Regulation of Allergic Airway Inflammation: Lessons from the AADCRC |
CME |
| 1808_Baseman |
2016 VAM: 1808 – Microbial Regulation of Allergic Airway Inflammation: Lessons from the AADCRC |
CME |
| 2101_Casale |
2016 VAM: 2101 – Immunoglobulin E: The First 50 Years and Beyond |
CME |
| 2101_Gould |
2016 VAM: 2101 – Immunoglobulin E: The First 50 Years and Beyond |
CME |
| 2101_Platts-Mills |
2016 VAM: 2101 – Immunoglobulin E: The First 50 Years and Beyond |
CME |
| 2306_Akdis |
2016 VAM: 2306 – Managing Stinging Insect Allergy in the 21st Century |
CME |
| 2306_Castells |
2016 VAM: 2306 – Managing Stinging Insect Allergy in the 21st Century |
CME |
| 2306_Golden |
2016 VAM: 2306 – Managing Stinging Insect Allergy in the 21st Century |
CME |
| 2307_Bonagura |
2016 VAM: 2307 – What Do I Do With These Abnormal Newborn Screening Results? |
CME |
| 2307_Kohn |
2016 VAM: 2307 – What Do I Do With These Abnormal Newborn Screening Results? |
CME |
| 2307_Sullivan |
2016 VAM: 2307 – What Do I Do With These Abnormal Newborn Screening Results? |
CME |
| 2312_Greenhawt |
2016 VAM: 2312 – Allied Health: Cutting Edge: Health Related Quality of Life and Allergy Disease |
CME |
| 2312_Turner |
2016 VAM: 2312 – Allied Health: Cutting Edge: Health Related Quality of Life and Allergy Disease |
CME |
| 2312_Venter |
2016 VAM: 2312 – Allied Health: Cutting Edge: Health Related Quality of Life and Allergy Disease |
CME |
| 2701_Holgate |
2016 VAM: 2701 – The Past, Present and Future of Asthma |
CME |
| 2802_Jackson |
2016 VAM: 2802 – Vocal Cord Dysfunction (VCD): More Common Than You Think |
CME |
| 2802_Petrov |
2016 VAM: 2802 – Vocal Cord Dysfunction (VCD): More Common Than You Think |
CME |
| 2802_Q&A |
2016 VAM: 2802 – Vocal Cord Dysfunction (VCD): More Common Than You Think |
CME |
| 2802_Tilles |
2016 VAM: 2802 – Vocal Cord Dysfunction (VCD): More Common Than You Think |
CME |
| 2804_Bender |
2016 VAM: 2804 – Adherence Challenges in Asthma: Pediatrics, Adolescents and Older Adults |
CME |
| 2804_Mosnaim |
2016 VAM: 2804 – Adherence Challenges in Asthma: Pediatrics, Adolescents and Older Adults |
CME |
| 2804_Nyenhuis |
2016 VAM: 2804 – Adherence Challenges in Asthma: Pediatrics, Adolescents and Older Adults |
CME |
| 2804_Panel Discussion and Q&A |
2016 VAM: 2804 – Adherence Challenges in Asthma: Pediatrics, Adolescents and Older Adults |
CME |
| 2809_Akdis |
2016 VAM: 2809 – Novel Biologicals for Asthma and Allergic Rhinosinusitis |
CME |
| 2809_Bachart |
2016 VAM: 2809 – Novel Biologicals for Asthma and Allergic Rhinosinusitis |
CME |
| 2809_Wenzel |
2016 VAM: 2809 – Novel Biologicals for Asthma and Allergic Rhinosinusitis |
CME |
| 2810_Corry |
2016 VAM: 2810 – Clinical Implications of Microbiome in Chronic Respiratory Disease |
CME |
| 2810_Huang |
2016 VAM: 2810 – Clinical Implications of Microbiome in Chronic Respiratory Disease |
CME |
| 2810_Huffnagle |
2016 VAM: 2810 – Clinical Implications of Microbiome in Chronic Respiratory Disease |
CME |
| 2815_Epstein |
2016 VAM: 2815 – When Writing a Script Just Isn’t Enough: Strategies to Overcome Barriers Associated with Poor Asthma Control in Older Adults |
CME |
| 2815_Ledford |
2016 VAM: 2815 – When Writing a Script Just Isn’t Enough: Strategies to Overcome Barriers Associated with Poor Asthma Control in Older Adults |
CME |
| 2815_Saltoun |
2016 VAM: 2815 – When Writing a Script Just Isn’t Enough: Strategies to Overcome Barriers Associated with Poor Asthma Control in Older Adults |
CME |
| 3303_Lucas |
2016 VAM: 3303 – Difficult Viral Infections Due to Defects in Innate Immunity |
CME |
| 3303_Mace |
2016 VAM: 3303 – Difficult Viral Infections Due to Defects in Innate Immunity |
CME |
| 3303_Schulart |
2016 VAM: 3303 – Difficult Viral Infections Due to Defects in Innate Immunity |
CME |
| 3304_Assaad |
2016 VAM: 3304 – Emerging and Current Diagnostics and Therapies for Eosinophilic Esophagitis |
CME |
| 3304_Ghaffari |
2016 VAM: 3304 – Emerging and Current Diagnostics and Therapies for Eosinophilic Esophagitis |
CME |
| 3304_McDonald |
2016 VAM: 3304 – Emerging and Current Diagnostics and Therapies for Eosinophilic Esophagitis |
CME |
| 3305_Bacharier |
2016 VAM: 3305 – Severe Asthma in Children: From Mechanisms to Disease Modification |
CME |
| 3305_Guilbert |
2016 VAM: 3305 – Severe Asthma in Children: From Mechanisms to Disease Modification |
CME |
| 3305_Jackson |
2016 VAM: 3305 – Severe Asthma in Children: From Mechanisms to Disease Modification |
CME |
| 3305_Q&A |
2016 VAM: 3305 – Severe Asthma in Children: From Mechanisms to Disease Modification |
CME |
| 3306_Durham |
2016 VAM: 3306 – Using SCIT vs. SLIT to Modify Allergic Disease |
CME |
| 3306_Passalacqua |
2016 VAM: 3306 – Using SCIT vs. SLIT to Modify Allergic Disease |
CME |
| 3306_Shamji |
2016 VAM: 3306 – Using SCIT vs. SLIT to Modify Allergic Disease |
CME |
| 4301_Brandt |
2016 VAM: 4301 – Novel Endotypes of Asthma: Lessons from the AADCRC |
CME |
| 4301_Laidlaw |
2016 VAM: 4301 – Novel Endotypes of Asthma: Lessons from the AADCRC |
CME |
| 4301_Woodruff |
2016 VAM: 4301 – Novel Endotypes of Asthma: Lessons from the AADCRC |
CME |
| 4305_Carlsten |
2016 VAM: 4305 – Immunologic Insights into Environmental Triggers of Asthma |
CME |
| 4305_Gern |
2016 VAM: 4305 – Immunologic Insights into Environmental Triggers of Asthma |
CME |
| 4305_Hershey |
2016 VAM: 4305 – Immunologic Insights into Environmental Triggers of Asthma |
CME |
| 4816_Akdis |
2016 VAM: 4816 – New Approaches to Induce Tolerance and Modify the Natural History of Allergic Diseases |
CME |
| 4816_Burks |
2016 VAM: 4816 – New Approaches to Induce Tolerance and Modify the Natural History of Allergic Diseases |
CME |
| 4816_Valenta |
2016 VAM: 4816 – New Approaches to Induce Tolerance and Modify the Natural History of Allergic Diseases |
CME |
| 1503 Kim |
#1503 ILC2: Gateway to Th2 Inflammation |
Non-CME |
| 1503 Molofsky |
#1503 ILC2: Gateway to Th2 Inflammation |
Non-CME |
| 1503_Kita |
#1503 ILC2: Gateway to Th2 Inflammation |
Non-CME |
| 1551_Discussion |
#1551 Allied Health: Precautionary Allergen Labeling Contains Useful Information |
Non-CME |
| 1551_Turner |
#1551 Allied Health: Precautionary Allergen Labeling Contains Useful Information |
Non-CME |
| 1551_Venter |
#1551 Allied Health: Precautionary Allergen Labeling Contains Useful Information |
Non-CME |
| 1601 Lemanske |
#1601 The Origins of Childhood Asthma |
Non-CME |
| 1601 Ober |
#1601 The Origins of Childhood Asthma |
Non-CME |
| 1804_Akdis |
#1804 B-Regulatory Cells: No Longer Playing Second Fiddle to T Regs |
Non-CME |
| 1804_Fallon |
#1804 B-Regulatory Cells: No Longer Playing Second Fiddle to T Regs |
Non-CME |
| 1804_Rothstein |
#1804 B-Regulatory Cells: No Longer Playing Second Fiddle to T Regs |
Non-CME |
| 2302_Dor |
#2302 Lessons from Performing Guideline-Drive, Evidence-Based Asthma Interventions in the Real World: Who Benefits? |
Non-CME |
| 2302_Kennedy |
#2302 Lessons from Performing Guideline-Drive, Evidence-Based Asthma Interventions in the Real World: Who Benefits? |
Non-CME |
| 2302_Q&A |
#2302 Lessons from Performing Guideline-Drive, Evidence-Based Asthma Interventions in the Real World: Who Benefits? |
Non-CME |
| 2302_Stevens |
#2302 Lessons from Performing Guideline-Drive, Evidence-Based Asthma Interventions in the Real World: Who Benefits? |
Non-CME |
| 2304_Kabashima |
#2304 Epithelium and Innate Immune Responses: Airways and Skin |
Non-CME |
| 2304_Kolls |
#2304 Epithelium and Innate Immune Responses: Airways and Skin |
Non-CME |
| 2304_Lee |
#2304 Epithelium and Innate Immune Responses: Airways and Skin |
Non-CME |
| 2305_Nadeau |
#2305 Epigenetic Mechanisms in Allergic Diseases |
Non-CME |
| 2305_Ober |
#2305 Epigenetic Mechanisms in Allergic Diseases |
Non-CME |
| 2305_Q&A |
#2305 Epigenetic Mechanisms in Allergic Diseases |
Non-CME |
| 2305_Raby |
#2305 Epigenetic Mechanisms in Allergic Diseases |
Non-CME |
| 2551_Gern |
#2551 Rhinovirus is More Important Than RSV in the Origin of Asthma |
Non-CME |
| 2551_Hartert |
#2551 Rhinovirus is More Important Than RSV in the Origin of Asthma |
Non-CME |
| 2552_Fleischer |
#2552 Are You Nuts? Penauts Should Not be Removed From Schools and Other Public Places |
Non-CME |
| 2552_Q&A |
#2552 Are You Nuts? Penauts Should Not be Removed From Schools and Other Public Places |
Non-CME |
| 2552_Wang |
#2552 Are You Nuts? Penauts Should Not be Removed From Schools and Other Public Places |
Non-CME |
| 2554_Cahalan |
#2554 Imaging Immunity in Health and Disease |
Non-CME |
| 3101_Beck |
#3101 Clinical Insight Into the Prevention and Modification of Atopic Disease |
Non-CME |
| 3101_Busse |
#3101 Clinical Insight Into the Prevention and Modification of Atopic Disease |
Non-CME |
| 3101_Lack |
#3101 Clinical Insight Into the Prevention and Modification of Atopic Disease |
Non-CME |
| 3302_Chatila |
#3302 T Cell Determination Heterogeneity and Hijacking in Allergic Disease |
Non-CME |
| 3302_Pepper |
#3302 T Cell Determination Heterogeneity and Hijacking in Allergic Disease |
Non-CME |
| 3302_Siegel |
#3302 T Cell Determination Heterogeneity and Hijacking in Allergic Disease |
Non-CME |
| 3551_Cianferoni-Pro |
#3551 Eosinophilic Esophagitis: A Primary Disease of the Esophageal Mucosa |
Non-CME |
| 3551_Debate |
#3551 Eosinophilic Esophagitis: A Primary Disease of the Esophageal Mucosa |
Non-CME |
| 3551_Spergel-Con |
#3551 Eosinophilic Esophagitis: A Primary Disease of the Esophageal Mucosa |
Non-CME |
| 3552_Q&A |
#3552 Skin Testing is Necessary Before Early Introduction of Peanut for Prevention of Peanut Allergy |
Non-CME |
| 3552_Sampson |
#3552 Skin Testing is Necessary Before Early Introduction of Peanut for Prevention of Peanut Allergy |
Non-CME |
| 3552_Tang |
#3552 Skin Testing is Necessary Before Early Introduction of Peanut for Prevention of Peanut Allergy |
Non-CME |
| 3553_Ballow-Con |
#3553 Should Antibiotic Prophylaxis Be Routinely Used in Patients With Antibody-Mediated Primary Immunodeficiency? |
Non-CME |
| 3553_Debate |
#3553 Should Antibiotic Prophylaxis Be Routinely Used in Patients With Antibody-Mediated Primary Immunodeficiency? |
Non-CME |
| 3553_Paris-Pro |
#3553 Should Antibiotic Prophylaxis Be Routinely Used in Patients With Antibody-Mediated Primary Immunodeficiency? |
Non-CME |
| 3701_Castro |
#3701 ADT: Asthma Endotypes: What are the Therapeutic Implications? |
Non-CME |
| 3701_Sands |
#3701 ADT: Asthma Endotypes: What are the Therapeutic Implications? |
Non-CME |
| 3702_Chatila |
#3702 BCI: Traffic Pollution Exposure and Allergic Disease: New Insights |
Non-CME |
| 3702_Hershey |
#3702 BCI: Traffic Pollution Exposure and Allergic Disease: New Insights |
Non-CME |
| 3703_Demain |
#3703 EORD: Importance of School Environments for Children with Asthma |
Non-CME |
| 3704_Dong |
#3704 FADDA: Novel IgE-Independent Pathways for Drug Reactions |
Non-CME |
| 3704_Saini |
#3704 FADDA: Novel IgE-Independent Pathways for Drug Reactions |
Non-CME |
| 3705_Bender |
#3705 HEDQ: Teleallergy: The Use of Technology to Enhance Practice and Research in Allergy/Immunology |
Non-CME |
| 3705_Mosnaim |
#3705 HEDQ: Teleallergy: The Use of Technology to Enhance Practice and Research in Allergy/Immunology |
Non-CME |
| 3706_Durham |
#3706 IRSO: New Perspectives in Allergy: The Relationship Between IgE Polysensitization and Multimorbidity |
Non-CME |
| 3706_Wagenmann |
#3706 IRSO: New Perspectives in Allergy: The Relationship Between IgE Polysensitization and Multimorbidity |
Non-CME |
| 3707_Pillai |
#3707 MAAI: Mechanistic Dissection of IgG4-Related Disease |
Non-CME |
| 3707_Zimmermann |
#3707 MAAI: Mechanistic Dissection of IgG4-Related Disease |
Non-CME |
| 4101_Aceves |
#4101 Plenary The Exposome: The Dynamic Role of the Environment in Shaping Risk for Disease |
Non-CME |
| 4101_Adamko |
#4101 Plenary The Exposome: The Dynamic Role of the Environment in Shaping Risk for Disease |
Non-CME |
| 4101_Gergen |
#4101 Plenary The Exposome: The Dynamic Role of the Environment in Shaping Risk for Disease |
Non-CME |
| 4303_Nadeau |
#4303 State-of-the-art: Update from the AADCRC Food Allergy Research Centers |
Non-CME |
| 4303_Shreffler |
#4303 State-of-the-art: Update from the AADCRC Food Allergy Research Centers |
Non-CME |
| 4303_Wambre |
#4303 State-of-the-art: Update from the AADCRC Food Allergy Research Centers |
Non-CME |
| 4304_Balestrieri |
#4304 Phospholipases A2 and Lipid Mediators in the Pathogenesis of Asthma |
Non-CME |
| 4304_Chilton |
#4304 Phospholipases A2 and Lipid Mediators in the Pathogenesis of Asthma |
Non-CME |
| 4304_Hallstrand |
#4304 Phospholipases A2 and Lipid Mediators in the Pathogenesis of Asthma |
Non-CME |
| 4803_Boguniewicz |
#4803 New Biological Therapies on the Horizon for Severe Allergic Dieases of the Airways and Skin |
Non-CME |
| 4803_Liu |
#4803 New Biological Therapies on the Horizon for Severe Allergic Dieases of the Airways and Skin |
Non-CME |
| 4813_Chiu |
#4813 Maintenance of Certification: Past, Present and Future |
Non-CME |
| 4813_Le |
#4813 Maintenance of Certification: Past, Present and Future |
Non-CME |
| 4813_Lee |
#4813 Maintenance of Certification: Past, Present and Future |
Non-CME |
| 101_Aceves |
Aceves – Emerging Biologic Therapy for EoE |
TIGERS |
| 101_Azouz |
Azouz – Loss of SPINK7 in Esophageal Epithelial Cells |
TIGERS |
| 101_Collins |
Collins – Guidelines for Diagnosis of EGID |
TIGERS |
| 101_Dellon |
Dellon – Epidemiology of EGID |
TIGERS |
| 101_Doshi |
|
TIGERS |
| 101_Furuta |
Furuta – Safety of Topical Glucocorticoids for EoE |
TIGERS |
| 101_Gonsavles |
Gonsavles – Consensus Guidelines for Non-EoE EGID |
TIGERS |
| 101_Guerrerio |
Guerrerio – Relationships with Connective Tissue Disorders and Other Syndromes |
TIGERS |
| 101_Gupta |
Gupta – Topical Glucocorticoid vs. Diet Therapy |
TIGERS |
| 101_Hirano |
Hirano – Treating Complications of EoE-Fibrosis |
TIGERS |
| 101_Katzka |
Katzka – New Modalities for Surveying the Esophagus |
TIGERS |
| 101_Kottyan |
Kottyan – Gene and Environment Interaction in EoE |
TIGERS |
| 101_Kottyan 2 |
Kottyan – 11q13 is an Allergic Risk-Locus that Increases EoE Risk and Increases LRRC32 Expression |
TIGERS |
| 101_Liacouras |
Liacouras – Consensus Guidelines for EoE |
TIGERS |
| 101_Markowitz |
|
TIGERS |
| 101_Q&A |
Q&A Part 1 |
TIGERS |
| 101_Q&A 2 |
Q&A Part 2 |
TIGERS |
| 101_Rothenberg |
Rothenberg – Pathogenesis of Disease |
TIGERS |
| 101_Shreffler |
Shreffler – Lymphocyte Involvement in EoE |
TIGERS |
| 101_Spergel |
Spergel – Role of Environmental in EoE |
TIGERS |
| 101_Straumann |
Straumann – Instruments for Monitoring Clinical Parameters in EoE |
TIGERS |
| 101_Warners |
Warners – Amino Acid-Based Diet Induces Histological Remission |
TIGERS |
| 101_Wechsler |
Wechsler – Mast Cells and Basophils in EoE |
TIGERS |
| 101_Wen |
Wen – PPI Responsive EoE |
TIGERS |
| 101_Wright |
Wright – Food Specific IgG4 Associated with EoE |
TIGERS |
| 1002_Chehade |
Difficult Cases |
Unlisted |
| 1002_Fonacier |
Difficult Cases |
Unlisted |
| 1002_Greenberger |
Difficult Cases |
Unlisted |
| 1002_Lee |
Difficult Cases |
Unlisted |
| 1002_Leonard |
Difficult Cases |
Unlisted |
| 1002_Reddy |
Difficult Cases |
Unlisted |
| 1201_Berin |
Allergen Immunotherapy, Today and Tomorrow: Session II. Immunotherapy with Food Allergens |
Unlisted |
| 1201_Jones |
Allergen Immunotherapy, Today and Tomorrow: Session II. Immunotherapy with Food Allergens |
Unlisted |
| 1201_Lack |
Allergen Immunotherapy, Today and Tomorrow: Session II. Immunotherapy with Food Allergens |
Unlisted |
| 1201_Nadeau |
Allergen Immunotherapy, Today and Tomorrow: Session II. Immunotherapy with Food Allergens |
Unlisted |
| 1201_Vickery |
Allergen Immunotherapy, Today and Tomorrow: Session II. Immunotherapy with Food Allergens |
Unlisted |
| 1202_Akin |
2016 VAM: 1202 – Diagnostic Challenges in Mastocytosis: Serum Tryptase, Allele-Specific PCR and GI Pathology |
CME |
| 1210_Kennedy |
The Principles of Healthy Homes and Using Home Environmental Assessment in Disease Management |
Unlisted |
| 1210_Phipatanakul |
The Principles of Healthy Homes and Using Home Environmental Assessment in Disease Management |
Unlisted |
| 1210_Portnoy |
The Principles of Healthy Homes and Using Home Environmental Assessment in Disease Management |
Unlisted |
| 1501 Renz |
JACI: Year-in-Review TICKETED |
Unlisted |
| 1810 Kertz |
Allied Health Plenary: Working Together to Improve Asthma Care |
Unlisted |
| 1810 Matsui |
Allied Health Plenary: Working Together to Improve Asthma Care |
Unlisted |
| 2303_Anthony |
Allied Health Plenary: Working Together to Improve Asthma Care |
Unlisted |
| 2303_Cheng |
Allied Health Plenary: Working Together to Improve Asthma Care |
Unlisted |
| 2303_Q&A |
Allied Health Plenary: Working Together to Improve Asthma Care |
Unlisted |
| 2303_Wesemann |
Allied Health Plenary: Working Together to Improve Asthma Care |
Unlisted |
| 2311_Fishbein |
Allied Health: Comorbidities of Atopic Dermatitis |
Unlisted |
| 2311_LeBovidge |
Allied Health: Comorbidities of Atopic Dermatitis |
Unlisted |
| 2311_Stone |
Allied Health: Comorbidities of Atopic Dermatitis |
Unlisted |
| 2553_Epstein 1 |
Allergen Immunotherapy: Dose Adjustment: Are They Needed for Local Reactions, Peaks of Season, Gaps in Treatment? |
Unlisted |
| 2553_Epstein 2 |
Allergen Immunotherapy: Dose Adjustment: Are They Needed for Local Reactions, Peaks of Season, Gaps in Treatment? |
Unlisted |
| 2553_Epstein 3 |
Allergen Immunotherapy: Dose Adjustment: Are They Needed for Local Reactions, Peaks of Season, Gaps in Treatment? |
Unlisted |
| 2553_Q&A |
Allergen Immunotherapy: Dose Adjustment: Are They Needed for Local Reactions, Peaks of Season, Gaps in Treatment? |
Unlisted |
| 2553_Tankersley 1 |
Allergen Immunotherapy: Dose Adjustment: Are They Needed for Local Reactions, Peaks of Season, Gaps in Treatment? |
Unlisted |
| 2553_Tankersley 2 |
Allergen Immunotherapy: Dose Adjustment: Are They Needed for Local Reactions, Peaks of Season, Gaps in Treatment? |
Unlisted |
| 2553_Tankersley 3 |
Allergen Immunotherapy: Dose Adjustment: Are They Needed for Local Reactions, Peaks of Season, Gaps in Treatment? |
Unlisted |
| 2555_Price |
Maintenance of Certification: Past, Present and Future |
Unlisted |
| 2555_Q&A |
Maintenance of Certification: Past, Present and Future |
Unlisted |
| 2555_Wasserman |
Maintenance of Certification: Past, Present and Future |
Unlisted |
| 2801_Dinakar |
AAP: Hot Topics in Pediatric Allergy TICKETED |
Unlisted |
| 2801_Keet |
AAP: Hot Topics in Pediatric Allergy TICKETED |
Unlisted |
| 2801_Schneider |
AAP: Hot Topics in Pediatric Allergy TICKETED |
Unlisted |
| 2803_Nadeau |
How Allergic Immune Responses are Initiated and Regulated: The Role of Epithelial Cells and Immune System in Allergic Diseases |
Unlisted |
| 2803_Ziegler |
How Allergic Immune Responses are Initiated and Regulated: The Role of Epithelial Cells and Immune System in Allergic Diseases |
Unlisted |
| 2806_Baroody |
Chronic Rhinosinusitis in Children |
Unlisted |
| 2806_Hamilos |
Chronic Rhinosinusitis in Children |
Unlisted |
| 2806_Hauswirth |
Chronic Rhinosinusitis in Children |
Unlisted |
| 2807_Druey |
How Bronchial Smooth Muscle Cells Make Airways Hyper-Responsive |
Unlisted |
| 2807_Grunstein |
How Bronchial Smooth Muscle Cells Make Airways Hyper-Responsive |
Unlisted |
| 2807_Liggett |
How Bronchial Smooth Muscle Cells Make Airways Hyper-Responsive |
Unlisted |
| 2812_Betschel |
A Comparison of HAE Guidelines: What’s New? TICKETED |
Unlisted |
| 2812_Craig |
A Comparison of HAE Guidelines: What’s New? TICKETED |
Unlisted |
| 2812_Q&A |
A Comparison of HAE Guidelines: What’s New? TICKETED |
Unlisted |
| 2812_Zuraw |
A Comparison of HAE Guidelines: What’s New? TICKETED |
Unlisted |
| 3301_Bindslev-Jensen |
EAACI: Managing Allergy at the Frontline |
Unlisted |
| 3301_Jutel |
EAACI: Managing Allergy at the Frontline |
Unlisted |
| 3301_Muraro |
EAACI: Managing Allergy at the Frontline |
Unlisted |
| 3307_ Von Mutius |
New Strategies for the Prevention of Allergic Diseases |
Unlisted |
| 3307_Lack |
New Strategies for the Prevention of Allergic Diseases |
Unlisted |
| 3307_Valovirta |
New Strategies for the Prevention of Allergic Diseases |
Unlisted |
| 4302_Bacharier |
Environmental and Lifestyle Influences on Childhood Asthma |
Unlisted |
| 4302_Jackson |
Environmental and Lifestyle Influences on Childhood Asthma |
Unlisted |
| 4306_Kwok |
Allergen Immunotherapy: From Mechanisms to Biomarkers |
Unlisted |
| 4306_Shamji |
Allergen Immunotherapy: From Mechanisms to Biomarkers |
Unlisted |
| 4306_Valenta |
Allergen Immunotherapy: From Mechanisms to Biomarkers |
Unlisted |
| 4308_Banerji |
The Spectrum of Angioedema: Bench to Bedside |
Unlisted |
| 4308_Saff |
The Spectrum of Angioedema: Bench to Bedside |
Unlisted |
| 4308_Zuraw |
The Spectrum of Angioedema: Bench to Bedside |
Unlisted |
| 4809_Martin II |
Indoor Air Pollution: New Risks and Health Effects |
Unlisted |
| 4809_Mendell |
Indoor Air Pollution: New Risks and Health Effects |
Unlisted |
| 4809_Pinkerton |
Indoor Air Pollution: New Risks and Health Effects |
Unlisted |
| 4810_Berin |
Sensitization to Food Allergens: Role of the Adaptive and Innate Immune System |
Unlisted |
| 4810_Cianferoni |
Sensitization to Food Allergens: Role of the Adaptive and Innate Immune System |
Unlisted |
| AORN Candidates Forum |
Unlisted |